(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 26.52% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Cytosorbents's revenue in 2025 is $34,352,442.On average, 5 Wall Street analysts forecast CTSO's revenue for 2025 to be $2,448,049,005, with the lowest CTSO revenue forecast at $2,326,522,674, and the highest CTSO revenue forecast at $2,547,342,611. On average, 5 Wall Street analysts forecast CTSO's revenue for 2026 to be $3,045,443,554, with the lowest CTSO revenue forecast at $2,572,527,137, and the highest CTSO revenue forecast at $3,513,775,256.
In 2027, CTSO is forecast to generate $4,551,302,375 in revenue, with the lowest revenue forecast at $4,372,812,540 and the highest revenue forecast at $4,685,138,349.